298 related articles for article (PubMed ID: 21893225)
1. Effects of one year daily teriparatide treatment on trabecular bone material properties in postmenopausal osteoporotic women previously treated with alendronate or risedronate.
Gamsjaeger S; Buchinger B; Zoehrer R; Phipps R; Klaushofer K; Paschalis EP
Bone; 2011 Dec; 49(6):1160-5. PubMed ID: 21893225
[TBL] [Abstract][Full Text] [Related]
2. Effects of alendronate and risedronate on bone material properties in actively forming trabecular bone surfaces.
Hofstetter B; Gamsjaeger S; Phipps RJ; Recker RR; Ebetino FH; Klaushofer K; Paschalis EP
J Bone Miner Res; 2012 May; 27(5):995-1003. PubMed ID: 22336962
[TBL] [Abstract][Full Text] [Related]
3. Bone quality of the newest bone formed after two years of teriparatide therapy in patients who were previously treatment-naïve or on long-term alendronate therapy.
Hofstetter B; Gamsjaeger S; Varga F; Dobnig H; Stepan JJ; Petto H; Pavo I; Klaushofer K; Paschalis EP
Osteoporos Int; 2014 Dec; 25(12):2709-19. PubMed ID: 25037600
[TBL] [Abstract][Full Text] [Related]
4. Effects of 1 year of daily teriparatide treatment on iliacal bone mineralization density distribution (BMDD) in postmenopausal osteoporotic women previously treated with alendronate or risedronate.
Misof BM; Paschalis EP; Blouin S; Fratzl-Zelman N; Klaushofer K; Roschger P
J Bone Miner Res; 2010 Nov; 25(11):2297-303. PubMed ID: 20683883
[TBL] [Abstract][Full Text] [Related]
5. Bone material properties in trabecular bone from human iliac crest biopsies after 3- and 5-year treatment with risedronate.
Durchschlag E; Paschalis EP; Zoehrer R; Roschger P; Fratzl P; Recker R; Phipps R; Klaushofer K
J Bone Miner Res; 2006 Oct; 21(10):1581-90. PubMed ID: 16995813
[TBL] [Abstract][Full Text] [Related]
6. Biomechanical effects of teriparatide in women with osteoporosis treated previously with alendronate and risedronate: results from quantitative computed tomography-based finite element analysis of the vertebral body.
Chevalier Y; Quek E; Borah B; Gross G; Stewart J; Lang T; Zysset P
Bone; 2010 Jan; 46(1):41-8. PubMed ID: 19800436
[TBL] [Abstract][Full Text] [Related]
7. Femoral strength in osteoporotic women treated with teriparatide or alendronate.
Keaveny TM; McClung MR; Wan X; Kopperdahl DL; Mitlak BH; Krohn K
Bone; 2012 Jan; 50(1):165-70. PubMed ID: 22015818
[TBL] [Abstract][Full Text] [Related]
8. Evidence that treatment with risedronate in women with postmenopausal osteoporosis affects bone mineralization and bone volume.
Fratzl P; Roschger P; Fratzl-Zelman N; Paschalis EP; Phipps R; Klaushofer K
Calcif Tissue Int; 2007 Aug; 81(2):73-80. PubMed ID: 17612779
[TBL] [Abstract][Full Text] [Related]
9. Comparative effects of teriparatide and strontium ranelate in the periosteum of iliac crest biopsies in postmenopausal women with osteoporosis.
Ma YL; Marin F; Stepan J; Ish-Shalom S; Möricke R; Hawkins F; Kapetanos G; de la Peña MP; Kekow J; Martínez G; Malouf J; Zeng QQ; Wan X; Recker RR
Bone; 2011 May; 48(5):972-8. PubMed ID: 21262402
[TBL] [Abstract][Full Text] [Related]
10. Response rate of bone mineral density to teriparatide in postmenopausal women with osteoporosis.
Gallagher JC; Rosen CJ; Chen P; Misurski DA; Marcus R
Bone; 2006 Dec; 39(6):1268-75. PubMed ID: 16884968
[TBL] [Abstract][Full Text] [Related]
11. Teriparatide in bisphosphonate-resistant osteoporosis: microarchitectural changes and clinical results after 6 and 18 months.
Jobke B; Muche B; Burghardt AJ; Semler J; Link TM; Majumdar S
Calcif Tissue Int; 2011 Aug; 89(2):130-9. PubMed ID: 21626160
[TBL] [Abstract][Full Text] [Related]
12. Teriparatide reduces bone microdamage accumulation in postmenopausal women previously treated with alendronate.
Dobnig H; Stepan JJ; Burr DB; Li J; Michalská D; Sipos A; Petto H; Fahrleitner-Pammer A; Pavo I
J Bone Miner Res; 2009 Dec; 24(12):1998-2006. PubMed ID: 19453263
[TBL] [Abstract][Full Text] [Related]
13. Differential effects of teriparatide and alendronate on bone remodeling in postmenopausal women assessed by histomorphometric parameters.
Arlot M; Meunier PJ; Boivin G; Haddock L; Tamayo J; Correa-Rotter R; Jasqui S; Donley DW; Dalsky GP; Martin JS; Eriksen EF
J Bone Miner Res; 2005 Jul; 20(7):1244-53. PubMed ID: 15940379
[TBL] [Abstract][Full Text] [Related]
14. Antiresorptives overlapping ongoing teriparatide treatment result in additional increases in bone mineral density.
Muschitz C; Kocijan R; Fahrleitner-Pammer A; Lung S; Resch H
J Bone Miner Res; 2013 Jan; 28(1):196-205. PubMed ID: 22836585
[TBL] [Abstract][Full Text] [Related]
15. Head-to-head comparison of risedronate vs. teriparatide on bone turnover markers in women with postmenopausal osteoporosis: a randomised trial.
Anastasilakis AD; Goulis DG; Polyzos SA; Gerou S; Koukoulis GN; Efstathiadou Z; Kita M; Avramidis A
Int J Clin Pract; 2008 Jun; 62(6):919-24. PubMed ID: 18422590
[TBL] [Abstract][Full Text] [Related]
16. Early responsiveness of women with osteoporosis to teriparatide after therapy with alendronate or risedronate.
Miller PD; Delmas PD; Lindsay R; Watts NB; Luckey M; Adachi J; Saag K; Greenspan SL; Seeman E; Boonen S; Meeves S; Lang TF; Bilezikian JP;
J Clin Endocrinol Metab; 2008 Oct; 93(10):3785-93. PubMed ID: 18682511
[TBL] [Abstract][Full Text] [Related]
17. Bone mineral and collagen quality in iliac crest biopsies of patients given teriparatide: new results from the fracture prevention trial.
Paschalis EP; Glass EV; Donley DW; Eriksen EF
J Clin Endocrinol Metab; 2005 Aug; 90(8):4644-9. PubMed ID: 15914535
[TBL] [Abstract][Full Text] [Related]
18. Bone material properties in actively bone-forming trabeculae in postmenopausal women with osteoporosis after three years of treatment with once-yearly Zoledronic acid.
Gamsjaeger S; Buchinger B; Zwettler E; Recker R; Black D; Gasser JA; Eriksen EF; Klaushofer K; Paschalis EP
J Bone Miner Res; 2011 Jan; 26(1):12-8. PubMed ID: 20645415
[TBL] [Abstract][Full Text] [Related]
19. Serum sclerostin levels positively correlate with lumbar spinal bone mineral density in postmenopausal women--the six-month effect of risedronate and teriparatide.
Polyzos SA; Anastasilakis AD; Bratengeier C; Woloszczuk W; Papatheodorou A; Terpos E
Osteoporos Int; 2012 Mar; 23(3):1171-6. PubMed ID: 21305266
[TBL] [Abstract][Full Text] [Related]
20. Overlapping and continued alendronate or raloxifene administration in patients on teriparatide: effects on areal and volumetric bone mineral density--the CONFORS Study.
Muschitz C; Kocijan R; Fahrleitner-Pammer A; Pavo I; Haschka J; Schima W; Kapiotis S; Resch H
J Bone Miner Res; 2014 Aug; 29(8):1777-85. PubMed ID: 24619763
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
